



EXPRESS SCRIPTS®

**Express Scripts, Inc.  
Pharmacy and Therapeutics Committee  
Proceedings  
December 4, 2008**

**Drug Evaluations**

The Committee reviewed the following new drugs.

- A. Cinryze™ (C1 inhibitor [human] for intravenous use [freeze-dried powder for reconstitution])**
- B. NutreStore™ (L-glutamine powder for oral solution)**
- C. Promacta® (eltrombopag tablets)**
- D. tetrabenazine tablets (Xenazine®)**
- E. dapsone 5% gel (Aczone® Gel)**

**New Indications for Existing Products**

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. Gamunex® (immune globulin intravenous [human], 10%)** - Treatment of chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.
- B. Zmax® (azithromycin extended release for oral suspension)** – Expanded the age indication from adults to adults and pediatric patients 6 months of age and older for the treatment of community-acquired pneumonia in patients appropriate for oral therapy.
- C. Apidra® (insulin glulisine [rDNA origin] injection)** – Expanded the age indication from adults to adults and children 4 through 17 years old to improve glycemic control in patients with diabetes mellitus.
- D. Seroquel XR™ (quetiapine fumarate extended-release tablets)** – Three new indications: 1) treatment of acute depressive episodes associated with bipolar I disorder (BP); 2) treatment of acute manic or mixed episodes associated with BP as monotherapy and as an adjunct lithium or divalproex therapy; and 3) maintenance treatment of BP as adjunct therapy to lithium or divalproex.
- E. Prezista® (darunavir tablets)** – Expanded the indication from treatment-experienced adult patients to both treatment-experienced and treatment-naïve adult patients for the treatment of human immunodeficiency virus (HIV)-1 infection.
- F. Treanda® (bendamustine hydrochloride for injection, for intravenous infusion)** – For the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- G. Norditropin® (somatropin [rDNA origin] injection)** – For the treatment of growth failure in children born small for gestational age with no catch-up by age 2 to 4 years.
- H. Ranexa® (ranolazine extended-release tablets)** – Expanded the indication from second-line chronic angina therapy to now allow for first-line use.
- I. Crestor® (rosuvastatin calcium tablets)** – As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia).

- J. Premarin® Vaginal Cream (conjugated estrogens vaginal cream)** – Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

**New Clinical Line Extensions**

The Committee reviewed one new clinical line extension.

- A. Venlafaxine (venlafaxine hydrochloride extended-release tablets/*Osmotica Pharmaceutical*)**